124 related articles for article (PubMed ID: 36652763)
21. Engineering a facile and versatile nanoplatform to facilitate the delivery of multiple agents for targeted breast cancer chemo-immunotherapy.
Bahreyni A; Mohamud Y; Zhang J; Luo H
Biomed Pharmacother; 2023 Jul; 163():114789. PubMed ID: 37119737
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
Noman MZ; Parpal S; Van Moer K; Xiao M; Yu Y; Viklund J; De Milito A; Hasmim M; Andersson M; Amaravadi RK; Martinsson J; Berchem G; Janji B
Sci Adv; 2020 May; 6(18):eaax7881. PubMed ID: 32494661
[TBL] [Abstract][Full Text] [Related]
23. Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
Liu J; Zhao Z; Qiu N; Zhou Q; Wang G; Jiang H; Piao Y; Zhou Z; Tang J; Shen Y
Nat Commun; 2021 Apr; 12(1):2425. PubMed ID: 33893275
[TBL] [Abstract][Full Text] [Related]
24. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
25. Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment.
Ruan S; Xie R; Qin L; Yu M; Xiao W; Hu C; Yu W; Qian Z; Ouyang L; He Q; Gao H
Nano Lett; 2019 Nov; 19(11):8318-8332. PubMed ID: 31610656
[TBL] [Abstract][Full Text] [Related]
26. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
[TBL] [Abstract][Full Text] [Related]
27. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
[TBL] [Abstract][Full Text] [Related]
28. Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy.
Xiang Y; Chen L; Liu C; Yi X; Li L; Huang Y
Small; 2022 Feb; 18(6):e2104591. PubMed ID: 34859582
[TBL] [Abstract][Full Text] [Related]
29. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework.
Ge YX; Zhang TW; Zhou L; Ding W; Liang HF; Hu ZC; Chen Q; Dong J; Xue FF; Yin XF; Jiang LB
Biomaterials; 2022 Mar; 282():121407. PubMed ID: 35217343
[TBL] [Abstract][Full Text] [Related]
31. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
32. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
[TBL] [Abstract][Full Text] [Related]
33. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
[TBL] [Abstract][Full Text] [Related]
34. Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
Zhang S; Huang Y; Pi S; Chen H; Ye F; Wu C; Li L; Ye Q; Lin Y; Su Z
J Nanobiotechnology; 2023 Oct; 21(1):360. PubMed ID: 37789342
[TBL] [Abstract][Full Text] [Related]
35. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
[TBL] [Abstract][Full Text] [Related]
36. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.
Limagne E; Nuttin L; Thibaudin M; Jacquin E; Aucagne R; Bon M; Revy S; Barnestein R; Ballot E; Truntzer C; Derangère V; Fumet JD; Latour C; Rébé C; Bellaye PS; Kaderbhaï CG; Spill A; Collin B; Callanan MB; Lagrange A; Favier L; Coudert B; Arnould L; Ladoire S; Routy B; Joubert P; Ghiringhelli F
Cancer Cell; 2022 Feb; 40(2):136-152.e12. PubMed ID: 35051357
[TBL] [Abstract][Full Text] [Related]
37. Ferrimagnetic Vortex Nanoring-Mediated Mild Magnetic Hyperthermia Imparts Potent Immunological Effect for Treating Cancer Metastasis.
Liu X; Zheng J; Sun W; Zhao X; Li Y; Gong N; Wang Y; Ma X; Zhang T; Zhao LY; Hou Y; Wu Z; Du Y; Fan H; Tian J; Liang XJ
ACS Nano; 2019 Aug; 13(8):8811-8825. PubMed ID: 31328922
[TBL] [Abstract][Full Text] [Related]
38. Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy.
Liu Y; Chen XG; Yang PP; Qiao ZY; Wang H
Biomacromolecules; 2019 Feb; 20(2):882-892. PubMed ID: 30621390
[TBL] [Abstract][Full Text] [Related]
39. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
[No Abstract] [Full Text] [Related]
40. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
